Eli Lilly and Company (NYSE:LLY) Shares Sold by Eagle Strategies LLC

Eagle Strategies LLC decreased its stake in Eli Lilly and Company (NYSE:LLY) by 11.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,075 shares of the company’s stock after selling 140 shares during the quarter. Eagle Strategies LLC’s holdings in Eli Lilly and Company were worth $973,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Tidemark LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth about $29,000. Core Wealth Advisors Inc. boosted its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares in the last quarter. Lynx Investment Advisory acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $32,000. LGT Financial Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $36,000. Finally, Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $37,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 194,978 shares of the business’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $885.91, for a total value of $172,732,959.98. Following the sale, the insider now directly owns 97,583,810 shares in the company, valued at approximately $86,450,473,117.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last three months, insiders sold 661,900 shares of company stock worth $604,721,602. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 2.2 %

NYSE LLY opened at $920.89 on Thursday. The business’s fifty day simple moving average is $896.20 and its 200-day simple moving average is $831.11. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The firm has a market cap of $875.22 billion, a PE ratio of 135.62, a P/E/G ratio of 2.73 and a beta of 0.42. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, equities analysts anticipate that Eli Lilly and Company will post 16.51 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Guggenheim lifted their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Berenberg Bank upped their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday. Finally, JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $961.76.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.